Patents by Inventor Jorg Holenz
Jorg Holenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100292279Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: May 12, 2010Publication date: November 18, 2010Applicant: ASTRAZENECA ABInventors: Johan Bylund, Maria E. Ek, Jörg Holenz, Annika Kers, Liselotte Öhberg
-
Publication number: 20100125087Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: AstraZeneca ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Laszlo RAKOS, Peter SODERMAN, Britt-Marie SWAHN, Stefan VON BERG, Fredrik VON KIESERITZKY
-
Publication number: 20100125081Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100125082Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100105680Abstract: The present invention relates to substituted dimethylcyclobutyl compounds of general formula I, a process for their preparation, medicaments comprising said substituted dimethylcyclobutyl compounds as well as the use of said substituted dimethylcyclobutyl compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via sigma receptors.Type: ApplicationFiled: August 3, 2007Publication date: April 29, 2010Inventors: Maria Rosa Cuberes Altisent, Jordi Corbera Arjona, Jorg Holenz, Rosa Maria Ortuno Mingarro, Sandra Izquierdo Salado
-
Patent number: 7629356Abstract: This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: GrantFiled: May 15, 2008Date of Patent: December 8, 2009Assignees: AstraZeneca AB, Astex TherapeuticsInventors: Gianni Chessari, Miles Stuart Congreve, Jörg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
-
Publication number: 20090281138Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: November 14, 2008Publication date: November 12, 2009Applicant: AstraZeneca ABInventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
-
Publication number: 20090233945Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 15, 2008Publication date: September 17, 2009Applicants: AstraZeneca AB, Astex Therapeutics LimitedInventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
-
Publication number: 20090163586Abstract: The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: December 17, 2008Publication date: June 25, 2009Applicant: AstraZeneca ABInventors: Johan Bylund, Maria E. Ek, Ylva Gravenfors, Jorg Holenz, Alexander Minidis, Gunnar Nordvall, Daniel Sohn, Karl S.A. Vallin, Jenny Viklund, Stefan Von Berg
-
Publication number: 20090131468Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: November 14, 2008Publication date: May 21, 2009Applicant: AstraZeneca ABInventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
-
Publication number: 20090076001Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compound corresponding to formula I, methods for producing them, to medicaments containing these compounds, the use of these compounds for producing medicaments and related treatment methodsType: ApplicationFiled: April 5, 2006Publication date: March 19, 2009Applicant: Gruenenthal GmbHInventors: Corinna Sundermann, Bernd Sundermann, Jorg Holenz, HagenHeinrich Hennies
-
Patent number: 7504519Abstract: The invention relates to derivatives of general formula (I), and to their pharmaceutically acceptable salts, their stereoisomeric forms, preferably their pure enantiomeric or diastereomeric forms and their racemic forms, or a mixture thereof in any mixture ratio, and their N-oxides and the corresponding solvates or hydrates, to the processes for obtaining said derivatives and to the pharmaceutical compositions which contain them. Said derivatives are useful as anti-inflammatory and analgesic agents.Type: GrantFiled: September 22, 2004Date of Patent: March 17, 2009Assignee: Laboratorios Del Dr. Esteve, S.A.Inventors: Rosa Cuberes Altisen, Jorg Holenz, Mario Colombo Piñol, Mercedes Port De Pol
-
Publication number: 20080287462Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 15, 2008Publication date: November 20, 2008Applicants: AstraZeneca AB, Astex Therapeutics LimitedInventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
-
Publication number: 20080253978Abstract: The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation.Type: ApplicationFiled: June 6, 2006Publication date: October 16, 2008Applicant: ISDIN, S.A.Inventors: Carles Trullas, Carles Pelejero, David Panyella, Jordi Corbera, Jorg Holenz, David Vano
-
Publication number: 20080214577Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 11, 2007Publication date: September 4, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Karin Kolmodin, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam
-
Patent number: 7417170Abstract: Methods for the dehydration of substituted 1-amino-3-aryl-butan-3-ol compounds for the preparation of substituted 3-aryl-butyl-amine compounds.Type: GrantFiled: December 6, 2005Date of Patent: August 26, 2008Assignee: Gruenenthal GmbHInventors: Wolfgang Hell, Markus Kegel, Bernhard Akteries, Helmut Buschmann, Jorg Holenz, Harmut Loebermann, Detlef Heller, Hans-Joachim Drexler, Stefan Gladow
-
Publication number: 20080193398Abstract: The present invention relates to new heptaazaphenalene derivatives of general Formula (I) and to methods for obtaining them. The physicochemical properties of said compounds allow them to be used as UV radiation absorbents.Type: ApplicationFiled: July 13, 2006Publication date: August 14, 2008Applicant: ISDIN, S.A.Inventors: Carles Trullas, Carles Pelejero, David Panyella Costa, Jordi Corbera, Jorg Holenz
-
Publication number: 20080176862Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 19, 2007Publication date: July 24, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jorg Holenz, Sofia Karlstrom, Jacob Kihlstrom, Johan Lindstrom, Laszlo Rakos
-
Publication number: 20080171771Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 13, 2007Publication date: July 17, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jorg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Ohberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20080058349Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 11, 2007Publication date: March 6, 2008Applicants: Astrazeneca AB, Astex Therapeutics LtdInventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam